<SEC-DOCUMENT>0001157523-20-000339.txt : 20200312
<SEC-HEADER>0001157523-20-000339.hdr.sgml : 20200312
<ACCEPTANCE-DATETIME>20200312160518
ACCESSION NUMBER:		0001157523-20-000339
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200312
FILED AS OF DATE:		20200312
DATE AS OF CHANGE:		20200312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		20708760

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52187973.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div><br>
  </div>
  <div>
    <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Washington, D.C. 20549</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER<br>
      PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE<br>
      SECURITIES EXCHANGE ACT OF 1934</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Dated March 12, 2020</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Commission File Number 001-36421</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">AURINIA PHARMACEUTICALS INC.</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">(Exact name of Registrant as specified in its charter)</div>
    <div>&#160;</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; color: #000000; font-weight: bold;">N/A</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">(Translation of Registrant&#8217;s Name)</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">#1203-4464 Markham Street<br>
      Victoria, British Columbia<br>
      V8Z7X8<br>
      (250) 708-4272<br>
      (Address and telephone number of registrant&#8217;s principal executive offices)</div>
    <div>&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div>&#160;</div>
    <div style="margin-left: 21.6pt; color: #000000;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000;">Form 20-F &#9744;&#160; Form 40-F &#9746;</div>
    <div>&#160;</div>
    <div style="margin-left: 21.6pt; color: #000000;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
    <div>&#160;</div>
    <div style="margin-left: 21.6pt; color: #000000;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 21.6pt; color: #000000;">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule
      12g3-2(b) under the Securities Exchange Act of 1934.</div>
    <div>&#160;</div>
    <div style="text-align: center; color: #000000;">Yes &#9746;&#160; No &#9744;</div>
    <div>&#160;</div>
    <div style="text-indent: 21.6pt; margin-right: 14.4pt; color: #000000;">This Form 6-K is hereby filed and incorporated by reference in the registrant&#8217;s Registration Statement on Form F-10 (File No. 333-222413).</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div>&#160;</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">SIGNATURES</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 21.6pt; margin-right: 3.6pt; color: #000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
      thereunto duly authorized.</div>
    <div>&#160;</div>
    <div style="color: #000000;">Dated: March 12, 2020</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z675511d7783c4d2f8285a644a3278891">

          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; font-weight: bold;" rowspan="1" colspan="2">Aurinia Pharmaceuticals Inc.</td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; padding-bottom: 2px;">By:<br>
            </td>
            <td style="width: 47%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Peter S. Greenleaf</td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%;">Name: Peter S. Greenleaf </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%;">Title: Chief Executive Officer</td>
          </tr>

      </table>
    </div>
    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-weight: 400;"><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">EXHIBIT INDEX</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zf0966f5cec3f49ae94cd206cc4e2fe44">

          <tr>
            <td style="width: 6%; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; color: #000000;">Exhibit</font><font style="text-indent: 0px; font-size: 5.1pt;"><br>
              </font></td>
            <td style="width: 4%; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 90%; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; color: #000000;">Description of Exhibit</font></td>
          </tr>
          <tr>
            <td style="width: 6%;">
              <div>&#160;</div>
            </td>
            <td style="width: 4%;" colspan="1">&#160;</td>
            <td style="width: 90%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%;"><a href="a52187973ex99_1.htm">99.1</a><br>
            </td>
            <td style="width: 4%;" colspan="1">&#160;</td>
            <td style="width: 90%;"><a href="a52187973ex99_1.htm">News Release - Aurinia Launches Resource Kit for People Living with Lupus Nephritis and Partners
                with National Kidney Foundation on Awareness Initiative.</a></td>
          </tr>

      </table>
    </div>
    <div><font style="font-weight: bold; color: #000000;"><br>
      </font></div>
    <div>&#160;</div>
    <div style="margin-right: 14.4pt; color: #000000;">Exhibit 99.1 included with this report on Form 6-K is hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-222413), as
      amended or supplemented.</div>
    <div>&#160;</div>
    <div><br>
    </div>
  </div>
  <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52187973ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div class="bw-release">
    <h1 style="text-align: center; list-style-position:inside;FONT-SIZE: 14pt;"> <b>Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative</b> </h1>
    <div class="bw-release-subhead">
      <p style="text-align: center; list-style-position:inside;"><b> <i>- Company recognizes World Kidney Day and National Kidney Month -</i> </b></p>
    </div>
    <div class="bw-release-body">
      <div class="bw-release-table-js bw-release-story">
        <p>VICTORIA, British Columbia--(BUSINESS WIRE)--March 12, 2020--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (&#8220;Aurinia&#8221; or the &#8220;Company&#8221;) , a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple
          inflammatory and autoimmune conditions, today announced new initiatives to support the lupus nephritis (LN) community and raise disease awareness on World Kidney Day, during National Kidney Month and beyond. These initiatives and resources
          include: </p>
        <ul style="list-style-type: disc;">
          <li> <b>#ALLINorange: </b>Through the ALL IN program,<b> </b>Aurinia is once again partnering with the National Kidney Foundation (NKF) on its #ALLINorange campaign throughout the month of March to raise awareness and understanding of LN. The
            ALL IN program is a source of information, resources, and support for those affected by LN and their care partners. ALL IN community members and those who newly register in March will receive #ALLINorange disease awareness bracelets to show
            support for National Kidney Month and the LN community. More information is available at www.allinforln.com. </li>
          <li> <b>ALL IN Lupus Nephritis Awareness Resource Kit: </b>Aurinia also launched today a new resource kit for people living with LN and their care partners. The kit was created with input from members of the LN community to help expand
            awareness and knowledge of lupus nephritis. The resource kit is available at www.allinforln.com/awarenesskit. </li>
        </ul>
        <p> There is currently no FDA-approved therapy for LN, which is inflammation of the kidneys caused by systemic lupus erythematosus (SLE) and represents a serious progression of SLE. LN affects up to 50% of the SLE patient population. </p>
        <p> &#8220;Observances such as National Kidney Month and World Kidney Day are a reminder that people living with lupus nephritis are affected by the severe symptoms and complications associated with this disease each and every day. We are honored to work
          together with the community to advance understanding of this serious disease,&#8221; said Neil Solomons, M.D. Chief Medical Officer at Aurinia. &#8220;The ALL IN program is a source of information, resources, and support for those affected by LN, and we are
          committed to continuing to build on materials and initiatives that benefit the community.&#8221; </p>
        <p> More information about LN is available at www.allinforln.com. Members of the LN community can also find and share these resources and information about LN on Facebook @AuriniaPharma during National Kidney Month. </p>
        <p> <b>About Lupus Nephritis</b> </p>
        <p> Lupus nephritis (LN) is an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and represents a serious progression of SLE. SLE is a chronic, complex and often disabling disorder. The disease is highly heterogeneous,
          affecting a wide range of organs and tissue systems. Unlike SLE, LN has straightforward disease outcomes (measuring proteinuria) where an early response correlates with long-term outcomes. In patients with LN, renal damage results in proteinuria
          and/or hematuria and a decrease in renal function as evidenced by reduced eGFR, and increased serum creatinine levels. LN is debilitating and costly and if poorly controlled, LN can lead to permanent and irreversible tissue damage within the
          kidney, resulting in end-stage renal disease (ESRD), thus making LN a serious and potentially life-threatening condition. </p>
        <div> </div>
        <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
          <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
            <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
        </div>
        <p> <b>About Aurinia </b> </p>
        <p> Aurinia Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by diseases with a high unmet medical need. The Company is
          currently developing an investigational drug for the treatment of lupus nephritis, focal segmental glomerulosclerosis and dry eye syndrome. The Company&#8217;s head office is in Victoria, British Columbia and focuses its development efforts globally.
          For further information, see our website at www.auriniapharma.com. </p>
        <p> <b>About National Kidney Foundation</b> </p>
        <p> The National Kidney Foundation (NKF) is the largest, most comprehensive, and longstanding patient-centric organization dedicated to the awareness, prevention, and treatment of kidney disease in the U.S. For more information about NKF, visit
          www.kidney.org. </p>
        <p> <b>Forward-Looking Statement</b> </p>
        <p> Certain of the statements made in this presentation may constitute forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. These
          forward-looking statements or information include but are not limited to statements or information with respect to lupus nephritis (LN), FSGS and Dry Eye Syndrome. </p>
        <p> Forward-looking information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aurinia to be materially different from
          any future results, performance or achievements expressed or implied by such forward-looking information. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary
          materially from those described in forward-looking statements or information. Accordingly, you should not place undue reliance on forward-looking statements or information. </p>
        <p> Except as required by law, Aurinia will not update forward-looking information. All forward-looking information contained in this presentation is qualified by this cautionary statement. Additional information related to Aurinia, including a
          detailed list of the risks and uncertainties affecting Aurinia and its business can be found in Aurinia&#8217;s most recent Annual Information Form available by accessing the Canadian Securities Administrators&#8217; System for Electronic Document Analysis
          and Retrieval (SEDAR) website at www.sedar.com or the U.S. Securities and Exchange Commission&#8217;s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar. </p>
      </div>
      <div class="bw-release-contact">
        <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
        <p> <b>Investors &amp; Corporate: </b><br>
          Glenn Schulman, PharmD, MPH <br>
          Corporate Communications, Aurinia <br>
          gschulman@auriniapharma.com </p>
        <p> <b>Media: </b><br>
          Krystle Gibbs <br>
          Ten Bridge Communications <br>
          krystle@tenbridgecommunications.com </p>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
